Aduro Biotech Inc. (NASDAQ:ADRO) insider Thomas W. Dubensky sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $12.68, for a total value of $317,000.00. Following the completion of the transaction, the insider now owns 55,424 shares in the company, valued at approximately $702,776.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Aduro Biotech Inc. (NASDAQ:ADRO) opened at 12.77 on Friday. The firm’s 50 day moving average price is $14.06 and its 200 day moving average price is $13.10. The stock’s market cap is $826.91 million. Aduro Biotech Inc. has a 52-week low of $7.26 and a 52-week high of $34.95.
Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.21. The company earned $39 million during the quarter, compared to the consensus estimate of $25.24 million. Aduro Biotech had a negative net margin of 23.69% and a negative return on equity of 9.23%. The business’s revenue for the quarter was up 306.3% compared to the same quarter last year. On average, analysts expect that Aduro Biotech Inc. will post ($1.39) EPS for the current year.
Several research firms recently commented on ADRO. Zacks Investment Research downgraded Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Canaccord Genuity reiterated a “buy” rating and issued a $30.00 price objective on shares of Aduro Biotech in a research note on Friday, August 5th. Finally, Roth Capital reiterated a “buy” rating and issued a $22.00 price objective on shares of Aduro Biotech in a research note on Monday, July 11th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Aduro Biotech has an average rating of “Hold” and a consensus target price of $22.00.
Large investors have recently made changes to their positions in the stock. Sphera Funds Management LTD. increased its stake in shares of Aduro Biotech by 41.7% in the first quarter. Sphera Funds Management LTD. now owns 170,000 shares of the company’s stock valued at $2,178,000 after buying an additional 50,000 shares during the period. American Century Companies Inc. purchased a new stake in shares of Aduro Biotech during the second quarter valued at $1,265,000. State Street Corp increased its stake in shares of Aduro Biotech by 33.0% in the first quarter. State Street Corp now owns 160,860 shares of the company’s stock valued at $2,062,000 after buying an additional 39,952 shares during the period. Alps Advisors Inc. increased its stake in shares of Aduro Biotech by 27.7% in the second quarter. Alps Advisors Inc. now owns 90,766 shares of the company’s stock valued at $1,027,000 after buying an additional 19,663 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Aduro Biotech by 0.6% in the first quarter. Franklin Resources Inc. now owns 893,210 shares of the company’s stock valued at $11,442,000 after buying an additional 5,527 shares during the period. 29.76% of the stock is owned by institutional investors.
About Aduro Biotech
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.